Correspondence 0001493152-24-003330 from Bone Biologics Corp (BBLG)

Bone Biologics Corp
Date: Jan. 22, 2024 · CIK: 0001419554 · Accession: 0001493152-24-003330

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-276412

Date

Jan. 22, 2024

Author

President

Form

CORRESP

Company

Bone Biologics Corp

Letter

Bone Biologics Corporation

Burlington Woods Drive, Suite 100

Burlington, MA 01803

January 22, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Attn: Jane Park

Re: Bone Biologics Corporation

Registration Statement on Form S-3

File No. 333-276412

Ladies and Gentlemen:

In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Bone Biologics Corporation, a Delaware corporation (the “Registrant”), hereby requests that the effectiveness of the registration statement on Form S-3 (File No. 333-276412), initially filed with the U.S. Securities and Exchange Commission on January 5, 2024, as amended by the Pre-Effective Amendment No. 1 filed on January 17, 2024, be accelerated so that the registration statement becomes effective at 4:00 p.m. Eastern Time on January 24, 2024 or as soon thereafter as practicable.

If you have any questions or comments, please contact Alexander R. McClean of Harter Secrest & Emery at (585) 231-1248.

Very truly yours,
Bone Biologics Corporation

Show Raw Text

CORRESP
1
filename1.htm

Bone
Biologics Corporation

2
Burlington Woods Drive, Suite 100

Burlington,
MA 01803

January
22, 2024

VIA
EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

Attn:
Jane Park

    Re:
    Bone
                                            Biologics Corporation

    Registration
    Statement on Form S-3

    File
    No. 333-276412

Ladies
and Gentlemen:

In
accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Bone Biologics Corporation, a Delaware corporation
(the “Registrant”), hereby requests that the effectiveness of the registration statement on Form S-3 (File No. 333-276412),
initially filed with the U.S. Securities and Exchange Commission on January 5, 2024, as amended by the Pre-Effective Amendment No. 1
filed on January 17, 2024, be accelerated so that the registration statement becomes effective at 4:00 p.m. Eastern Time on January 24,
2024 or as soon thereafter as practicable.

If
you have any questions or comments, please contact Alexander R. McClean of Harter Secrest & Emery at (585) 231-1248.

    Very truly yours,

    Bone Biologics Corporation

    By:
    /s/
    Jeffrey Frelick

    Jeffrey
    Frelick

    President
    and Chief Executive Officer

SecProbe.io